Skip to main content
SpringerLink
Log in

Prostata- und Harnblasenkarzinom

Detektion von disseminierten Tumorzellen im Knochenmark

Prostate and bladder cancer

Detection of disseminated tumor cells in bone marrow

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die Prognose bei Patienten mit einem Prostata- oder Blasenkarzinom wird hauptsächlich durch den Nachweis vorliegender Metastasen bestimmt. Dabei wird in der klinischen Routine praktisch nur über das Lymphknotenstaging eine Metastasierung untersucht. Der Nachweis und die Charakterisierung disseminierter Tumorzellen im peripheren Blut oder im Knochenmark ist ein weiterer Parameter, der Aussagen über den Krankheitsverlauf zulässt. In diesem Artikel soll daher die Datenlage über die Wertigkeit disseminierter Tumorzellen im Knochenmark und eine mögliche Translation in die klinische Routine dargestellt werden.

Abstract

The prognosis of prostate and bladder cancer patients is predominantly determined by the detection of distant sites of metastasis. In clinical routine, virtually only lymph node staging is of relevance to determine metastasis. Detection and characterization of disseminated tumor cells in peripheral blood or bone marrow is an additional parameter of prognostic significance. In this article, we will summarize recent progress on the prognostic value of disseminated tumor cells in bone marrow and its translation into routine clinical analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597

    Article  CAS  PubMed  Google Scholar 

  2. Weckermann D, Müller P, Wawroschek F et al (1999) Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol 17(11):3438–3443

    CAS  PubMed  Google Scholar 

  3. Weckermann D, Müller P, Wawroschek F et al (2001) Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 166(2):699–704

    Article  CAS  PubMed  Google Scholar 

  4. Weckermann D, Polzer B, Ragg T et al (2009) Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27(10):1549–1556

    Article  PubMed  Google Scholar 

  5. Ricci E, Mattei E, Dumontet C et al (2013) Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate 73(16):1738–1746

    Article  CAS  PubMed  Google Scholar 

  6. Taichman RS, Patel LR, Bedenis R et al (2013) GAS 6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One 8(4):61873

    Article  Google Scholar 

  7. Murray NP, Reyes E, Tapia P et al (2012) Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocytochemical study. Bone Marrow Res 2012:259–351

    Article  Google Scholar 

  8. Pedersen EA, Shiozawa Y, Pienta KJ, Taichman RS (2012) The prostate cancer bone marrow niche: more than just ‚fertile soil’. Asian J Androl 14(3):423–427

    Article  PubMed Central  PubMed  Google Scholar 

  9. Shiozawa Y, Pienta KJ, Taichman RS (2011) Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res 17(17):5553–5558

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4):1298–1312

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Yu C, Shiozawa Y, Taichman RS et al (2012) Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr 22(2):131–148

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Joseph J, Shiozawa Y, Jung Y et al (2012) Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol Cancer Res 10(3):282–292

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Pluijm G van der (2011) Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 48(1):37–43

    Article  PubMed  Google Scholar 

  14. Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802

    Article  CAS  PubMed  Google Scholar 

  15. Hofmann T, Riesenberg R, Buchner A et al (2003) Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators. J Urol 169(4):1303–1307

    Article  CAS  PubMed  Google Scholar 

  16. Hofmann T, Buchner A, Hofstetter A et al (2007) Prognostic relevance of disseminated tumour cells in bone marrow of patients with transitional cell carcinoma. Eur J Cancer 43(18):2678–2684

    Article  CAS  PubMed  Google Scholar 

  17. Retz M, Lehmann J, Röder C et al (2001) Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients. Eur Urol 39(5):507–517

    Article  CAS  PubMed  Google Scholar 

  18. Retz M, Rotering J, Nawroth R et al (2011) Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow. Eur Urol 60(2):231–238

    Article  PubMed  Google Scholar 

  19. Marin-Aguilera M, Mengual L, Ribal MJ et al (2012) Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology 79(1):240 9–15

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. R. Nawroth, D. Weckermann und M. Retz geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Straße 22, 81675, München, Deutschland

    R. Nawroth & M. Retz

  2. Urologische Klinik, Klinikum Augsburg, Augsburg, Deutschland

    D. Weckermann

Authors
  1. R. Nawroth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Weckermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Nawroth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nawroth, R., Weckermann, D. & Retz, M. Prostata- und Harnblasenkarzinom. Urologe 53, 514–518 (2014). https://doi.org/10.1007/s00120-014-3445-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-014-3445-0

Schlüsselwörter

Keywords

Search

Navigation